1. Anti-tumor therapy through high ROS performance induced by Ag nanoenzyme from boron cluster with halloysite clay nanotubes.
- Author
-
Deng X, Xu X, Xia S, Wang Z, Li Y, Huang T, Wei Y, and Zhang H
- Subjects
- Animals, Mice, Humans, Cell Proliferation drug effects, Drug Screening Assays, Antitumor, Particle Size, Surface Properties, Cell Line, Tumor, Cell Survival drug effects, Hydroxyl Radical chemistry, Catalysis, Clay chemistry, Silver chemistry, Silver pharmacology, Nanotubes chemistry, Reactive Oxygen Species metabolism, Antineoplastic Agents pharmacology, Antineoplastic Agents chemistry, Boron chemistry, Boron pharmacology, Metal Nanoparticles chemistry
- Abstract
The conventional silver nanoparticles (Ag NPs) are characterized with high loading rate and stacking phenomenon, leading to shedding caused biotoxicity and low catalytic efficiency. This seriously hinders their application in biomedicine. Here, we modified the highly dispersible Ag NPs and Ag single-atoms (SAs) synthesis by combining the halloysite clay nanotubes (HNTs) and dodecahydro-dodecaborate (closo-[B
12 H12 ]2- ) to increase the biocompatible properties and decrease the loading rate. This novel Ag single-atom nanoenzyme alongside Ag NPs nanoenzyme avoid the elevated-temperature calcination while maintaining the exceptionally high-level efficiency of Ag utilization via the reducibility and coordination stabilization of closo-[B12 H12 ]2- and HNTs. With theoretical calculation and electron paramagnetic resonance, we confirmed that both Ag SAzymes and Ag NPs in HNT@B12 H12 @Ag nanoenzyme are capable decompose the H2 O2 into hydroxyl radical (·OH). For the application, we investigated the catalytic activity in the tumor cells and antitumor effects of HNT@B12 H12 @Ag nanoenzyme both in vitro and in vivo, and confirmed that it effectively suppressed melanoma growth through ·OH generation, with limited biotoxicity. This study provides a novel Ag nanoenzyme synthesis approach to increase the possibility of its clinical application., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier B.V. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF